The United States and Canadian Academy of Pathology's mission is to provide pathologists with high quality continuing
medical education (CME) at all levels of pathology practice and to reinforce and update attendees' knowledge of
pathology in their area(s) of interest and educational needs. This mission is accomplished by a - CME program that
includes lectures, seminars, symposia, interactive courses, question and answer sessions, and online courses and
teaching modules on various topics and forums of intellectual and professional interests. The participants engage in
presentation, discussion and critical evaluation of the scientific, technological and methodological advances in human
health and disease.
The USCAP's zero-tolerance policy for any real or perceived commercial bias in CME programs is a fundamental principle
that guides our interaction with industry. It is our goal to avoid even the appearance of a conflict of interest between
the USCAP and industry.
USCAP policies are based upon the guidelines established by the Accreditation Council for Continuing Medical Education (ACCME).
CME Programs at USCAP meetings are developed and implemented primarily by the USCAP's Education Committee. Industry has no
role in selecting program topics, faculty, or course directors, or influencing CME content. Industry influence or promotion
of on-line CME activities is prohibited. All speakers must disclose, prior to their presentation, if they or their
spouse/partner have any significant financial or other relationship with any commercial entity, irrespective of their
presentation topic. This applies to current relationships as well as those for the previous twelve months. These disclosures
are published in our meeting materials before the presentations. Members of USCAP Committees must also make these same
disclosures prior to their participation in committee meetings where decisions are made regarding USCAP educational programs.
The USCAP benefits from its partnership with corporate sponsors who provide financial support for a variety of non-CME
activities and programs. The USCAP does not accept commercial support for any particular CME activity. The USCAP recognizes
members' concerns regarding industry involvement and the potential for commercial bias, overt or otherwise. The USCAP regularly
reviews and revises its guidelines that govern industry participation to ensure that they are appropriate, comprehensive, and
unambiguous. Commercial Exhibitors are required to sign letters of agreement explicitly stating that they have had no input
into decision making regarding selection of educational programs, content or faculty and that they understand and will adhere
to USCAP guidelines.
The USCAP has revised its online evaluation forms to provide attendees with the opportunity to report any perceived commercial
bias. The USCAP Education Committee and CME Subcommittee, together with the USCAP staff, investigate and act on any infractions
or perceptions of bias in a rigorous and impartial manner. They may also seek further input on these or other ethical issues
from the USCAP ad hoc Ethics Committee.
The USCAP values its partnership with industry. However, the USCAP will not compromise the independence and credibility of its
scientific and CME programs through its relationships with corporate sponsors. Appropriate guidelines, as well as input from
attendees, are essential to maintain our integrity as an organization and the confidence that pathology professionals have
placed in the USCAP. Questions related to these issues may be addressed to Dr. Bruce Smoller, Executive Vice-President of the USCAP:
May 15, 2012
Approved by the USCAP CME Subcommittee
Bradley Quade, Chair